BOULDER, Colo. & NEW YORK–(BUSINESS WIRE)–Infleqtion, a global leader in neutral atom–based quantum technology, and Churchill Capital Corp X (NASDAQ: CCCX), a publicly traded special purpose acquisition company, today announced they have entered into a definitive business combination agreement, with the aim to accelerate Infleqtion’s mission to commercialize quantum products that provide orders of magnitude improvement in computing and precision sensing applications. Upon closing, the combine
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
